Recombinant Human Coagulation FVIII

DRUG4 trials

Sponsors

Sinocelltech Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

Hemophilia A

Phase 3

Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A

CompletedNCT03815318

Sinocelltech Ltd.Hemophilia A

Start: 2019-01-21End: 2020-01-16Updated: 2020-02-06

Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A.

Sinocelltech Ltd.Hemophilia A

Start: 2019-12-20End: 2020-09-20Target: 70Updated: 2019-05-13

Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Hemophilia A

Start: 2019-05-15End: 2020-03-31Target: 64Updated: 2019-08-19

Phase 4

Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.

Sinocelltech Ltd.Hemophilia A

Start: 2019-07-26End: 2025-04-01Target: 240Updated: 2020-04-28

Related Papers

P1670: LONG TERM SAFETY AND EFFICACY OF RECOMBINANT HUMAN COAGULATION FACTOR VIII (SCT800) IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A

HemaSphere2022-06-01